Ultragenyx Pharmaceutical
RARE
#5354
Rank
NZ$2.78 B
Marketcap
NZ$28.23
Share price
2.75%
Change (1 day)
-53.95%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2026 (TTM): -NZ$0.88 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are NZ$0.71 Billion. In 2025 the company made an earning of -NZ$0.9 Billion a decrease over its 2024 earnings that were of -NZ$0.89 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -NZ$0.88 Billion-1.98%
2025 -NZ$0.9 Billion1%
2024 -NZ$0.89 Billion-6.99%
2023 -NZ$0.96 Billion-17.65%
2022 -NZ$1.16 Billion55.52%
2021 -NZ$0.75 Billion178.53%
2020 -NZ$0.27 Billion-59.64%
2019 -NZ$0.67 Billion1.46%
2018 -NZ$0.66 Billion12.9%
2017 -NZ$0.58 Billion32.63%
2016 -NZ$0.44 Billion67.87%
2015 -NZ$0.26 Billion160.2%
2014 -NZ$99.68 Million66.64%
2013 -NZ$59.82 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Lexicon Pharmaceuticals
LXRX
-NZ$0.11 Billion-87.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
NZ$0.13 B-115.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
NZ$0.33 M-100.04%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
NZ$0.26 B-129.49%๐Ÿ‡บ๐Ÿ‡ธ USA